Since the Model for End-Stage Liver Disease (MELD) is indicative of severe liver disease and commonly used for the assessment of patients with liver failure, it was selected as a reference to assess the predictive ability of Gal-9 for the prognosis of patients with ACLF. This evidence concerns the gene LGALS9 and liver failure.